logo-loader

BioCorRx seeks FDA approval on its anti-opioid and alcoholism naltrexone implant

Published: 16:17 19 Feb 2019 EST

BioCorRx Inc (OTCQB: BICX) CEO Brady Granier tells Proactive Investors the California-based developer of substance use disorders treatments has been awarded a $5.7 million, two-year grant from the National Institutes of Health for the development of BICX102, the company’s sustained release naltrexone implant for the treatment of opioid use addiction and alcoholism.

Granier says once the implant is approved, he envisions the company attaching its cognitive behavioral therapy and peer support program to provide more tools for physicians prescribing the product.

Full interview: BioCorRx offers medical professionals free use of its...

BioCorRx Inc (OTCQB:BICX) CEO Brady Granier tells Proactive the California-based company will help support vulnerable patients recover from alcohol or drug dependencies through the coronavirus pandemic. Granier says the addiction treatment solutions company is offering free access to its...

on 04/07/2020